RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2011; 136(17): 898-903
DOI: 10.1055/s-0031-1275826
DOI: 10.1055/s-0031-1275826
Übersicht | Review article
Endokrinologie, Osteologie© Georg Thieme Verlag KG Stuttgart · New York
Neue Targets in der Osteoporosetherapie
New targets for treatment of osteoporosisWeitere Informationen
Publikationsverlauf
eingereicht: 15.11.2010
akzeptiert: 14.4.2011
Publikationsdatum:
26. April 2011 (online)

Schlüsselwörter
Osteoporose - Osteoklastogenese - Zielmoleküle
Keywords
osteoporosis - osteoclastogenesis - target molecules
Literatur
- 1
Bodine P V, Stauffer B, Ponce-de-Leon H. et al .
A small molecule inhibitor
of the Wnt antagonist secreted frizzled-related protein-1 stimulates
bone formation.
Bone.
2009;
44
1063-1068
MissingFormLabel
- 2
Bone H G, McClung M R, Roux C. et al .
Odanacatib, a cathepsin-K inhibitor for
osteoporosis: a two-year study in postmenopausal women with low
bone density.
J Bone Miner Res.
2010;
25
937-947
MissingFormLabel
- 3
Chantry A D, Heath D, Mulivor A W. et al .
Inhibiting activin-A signaling stimulates
bone formation and prevents cancer induced bone destruction in vivo.
J Bone Miner Res.
2010;
25
2357-2570
MissingFormLabel
- 4
Cox D, Brennan M, Moran N.
Integrins as therapeutic targets: lessons and opportunities.
Nat Rev Drug Discov.
2010;
9
804-820
MissingFormLabel
- 5
Eisman J A, Bone H G, Hosking D J. et al .
Odanacatib in the treatment
of postmenopausal women with low bone mineral density.
J
Bone Miner Res.
2011;
26
242-251
MissingFormLabel
- 6
Fajardo R J, Manoharan R K, Pearsall R S. et al .
Treatment with
a soluble receptor for activin improves bone mass and structure
in the axial and appendicular skeleton of female cynomolgus macaques
(Macaca fascicularis).
Bone.
2010;
46
64-71
MissingFormLabel
- 7
Henriksen D B, Alexandersen P, Hartmann B. et al .
Disassociation of bone resorption and formation
by GLP-2: a 14-day study in healthy postmenopausal women.
Bone.
2007;
40
723-729
MissingFormLabel
- 8
Henriksen D B, Alexandersen P, Hartmann B. et al .
Four-month treatment with GLP-2 significantly
increases hip BMD.
Bone.
2009;
45
833-842
MissingFormLabel
- 9
Hofbauer L C, Kuhne C A, Viereck V.
The OPG/RANKL/RANK system in metabolic bone
diseases.
J Musculoskelet Neuronal Interact.
2004;
4
268-725
MissingFormLabel
- 10
Iqbal J, Sun L, Zaidi M.
Denosumab
for the treatment of osteoporosis.
Curr Osteoporos Rep.
2010;
8
163-167
MissingFormLabel
- 11
Jakob F, Seefried L, Ebert R.
Pathophysiologie des Knochenstoffwechsels.
Internist.
2008;
49
1159-1164
MissingFormLabel
- 12
Jakob F.
Metabolische Knochenerkrankungen.
Internist.
2007;
48
1101-1107
MissingFormLabel
- 13
Jakob F, Benisch P, Klotz B. et
al .
Sexualsteroide in der Homöostase des Knochens.
Osteologie/Osteology.
2010;
2
105-110
MissingFormLabel
- 14
Jensen E D, Gopalakrishnan R, Westendorf J J.
Regulation of gene expression in osteoblasts.
Biofactors.
2010;
36
25-32
MissingFormLabel
- 15
Kamiya N, Kobayashi T, Mochida Y. et al .
Wnt inhibitors Dkk1 and Sost are downstream
targets of BMP signaling through the type IA receptor (BMPRIA) in
osteoblasts.
J Bone Miner Res.
2010;
25
200-210
MissingFormLabel
- 16
Kartal-Kaess M, Shore E M. et al .
Fibrodysplasia
ossificans progressiva (FOP): watch the great toes!.
Eur
J Pediatr.
2010;
169
1417-1421
MissingFormLabel
- 17
Kasten P, Beyen I, Bormann D, Luginbuhl R, Ploger F, Richter W.
The effect of two point
mutations in GDF-5 on ectopic bone formation in a beta-tricalciumphosphate
scaffold.
Biomaterials.
2010;
31
3878-3884
MissingFormLabel
- 18
Koncarevic A, Cornwall-Brady M, Pullen A. et al .
A soluble activin receptor type IIb prevents
the effects of androgen deprivation on body composition and bone
health.
Endocrinology.
2010;
151
4289-4300
MissingFormLabel
- 19
Kramer I, Halleux C, Keller H. et al .
Osteocyte Wnt/beta-catenin signaling
is required for normal bone homeostasis.
Mol Cell Biol.
2010;
30
3071-3085
MissingFormLabel
- 20
Kramer I, Keller H, Leupin O, Kneissel M.
Does osteocytic SOST
suppression mediate PTH bone anabolism?.
Trends Endocrinol
Metab.
2010;
21
237-244
MissingFormLabel
- 21
Kramer I, Loots G G, Studer A, Keller H, Kneissel M.
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST
overexpressing and deficient mice.
J Bone Miner Res.
2010;
25
178-189
MissingFormLabel
- 22
Lewiecki E M.
Denosumab – an emerging treatment for postmenopausal
osteoporosis.
Expert Opin Biol Ther.
2010;
10
467-476
MissingFormLabel
- 23
Lotinun S, Pearsall R S, Davies M V. et al .
A soluble activin receptor
Type IIA fusion protein (ACE-011) increases bone mass via a dual
anabolic-antiresorptive effect in Cynomolgus monkeys.
Bone.
2010;
46
1082-1088
MissingFormLabel
- 24
Marie P J.
The calcium-sensing receptor in bone cells: a potential therapeutic
target in osteoporosis.
Bone.
2010;
46
571-576
MissingFormLabel
- 25
Mason J J, Williams B O.
SOST and
DKK: Antagonists of LRP family signaling as targets for treating
bone disease.
J Osteoporos.
2010;
2010
460 120
MissingFormLabel
- 26
Matsumoto T, Abe M.
TGF-beta-related mechanisms
of bone destruction in multiple myeloma.
Bone.
2011;
48
129-134
MissingFormLabel
- 27
Moester M J, Papapoulos S E, Lowik C W, van Bezooijen R L.
Sclerostin: current knowledge and future perspectives.
Calcif
Tissue Int.
2010;
87
99-107
MissingFormLabel
- 28
Nakashima A, Katagiri T, Tamura M.
Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2)
signaling in differentiation pathway of C2C12 myoblasts.
J
Biol Chem.
2005;
280
37 660-37 668
MissingFormLabel
- 29
Raggatt L J, Partridge N C.
Cellular
and molecular mechanisms of bone remodeling.
J Biol Chem.
2010;
285
25 103-25 108
MissingFormLabel
- 30
Ralston S H, Uitterlinden A G.
Genetics
of osteoporosis.
Endocr Rev.
2010;
31
629-662
MissingFormLabel
- 31
Rizzoli R, Yasothan U, Kirkpatrick P.
Denosumab.
Nat Rev Drug Discov.
2010;
9
591-592
MissingFormLabel
- 32
Saidak Z, Brazier M, Kamel S, Mentaverri R.
Agonists and allosteric modulators
of the calcium-sensing receptor and their therapeutic applications.
Mol Pharmacol.
2009;
76
1131-1144
MissingFormLabel
- 33
Saylor P J, Smith M R.
Bone health
and prostate cancer.
Prostate Cancer Prostatic Dis.
2010;
13
20-27
MissingFormLabel
- 34
Seeman E.
Bone modeling and remodeling.
Crit Rev Eukaryot Gene Expr.
2009;
19
219-233
MissingFormLabel
- 35
Shore E M, Kaplan F S.
Inherited human
diseases of heterotopic bone formation.
Nat Rev Rheumatol.
2010;
6
518-527
MissingFormLabel
- 36
Sieber C, Kopf J, Hiepen C, Knaus P.
Recent advances in BMP receptor signaling.
Cytokine Growth Factor Rev.
2009;
20
343-355
MissingFormLabel
- 37
Tamura M, Nemoto E, Sato M M, Nakashima A, Shimauchi H.
Role of the Wnt signaling pathway in bone and tooth.
Front
Biosci (Elite Ed).
2010;
2
1405-1413
MissingFormLabel
- 38
Trivedi R, Goswami R, Chattopadhyay N.
Investigational anabolic therapies for osteoporosis.
Expert
Opin Investig Drugs.
2010;
19
995-1005
MissingFormLabel
- 39
Trivedi R, Mithal A, Chattopadhyay N.
Anabolics in osteoporosis: the emerging therapeutic tool.
Curr Mol Med.
2010;
10
14-28
MissingFormLabel
- 40
Wagner D O, Sieber C, Bhushan R, Borgermann J H, Graf D, Knaus P.
BMPs: from bone to body
morphogenetic proteins.
Sci Signal.
2010;
3
mr1
MissingFormLabel
- 41
Walsh D W, Godson C, Brazil D P, Martin F.
Extracellular BMP-antagonist
regulation in development and disease.
Trends Cell Biol.
2010;
20
244-256
MissingFormLabel
- 42
Walsh J S, Henriksen D B.
Feeding
and bone.
Arch Biochem Biophys.
2010;
503
11-19
MissingFormLabel
- 43
Yaccoby S.
Osteoblastogenesis and tumor growth in myeloma.
Leuk Lymphoma.
2010;
51
213-220
MissingFormLabel
- 44
Jakob F, Benisch P, Bhushan R, Ebert R, Seefried L, Schieker M, Ignatius A.
Zelluläre Defekte und Regulationsstörungen
bei der Heilung osteoporotischer Frakturen.
Osteologie.
2011;
20
23-28
MissingFormLabel
- 45
Seefried L , Ebert R, Müller-Deubert S. et al .
Mechanotransduktion im Alter
und bei Osteoporose.
Osteologie.
2010;
19
232-239
MissingFormLabel
Prof. Dr. Franz Jakob
Orthopädisches Zentrum für Muskuloskelettale
Forschung
Brettreichstraße 11
97074
Würzburg
Telefon: 0931/8031580
Fax: 0931/8031599
eMail: f-jakob.klh@uni-wuerzburg.de